Krystal Biotech, Inc.

KRYS

$261.41

Name : Krystal Biotech, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $7,580,241,920.00

EPSttm : 6.67

Krystal Biotech, Inc.

$261.41

5.02%

$12.50

Float Short %

10.91

Margin Of Safety %

-14

Put/Call OI Ratio

0.56

EPS Next Q Diff

-1.14

EPS Last/This Y

3.42

EPS This/Next Y

1.91

Price

261.58

Target Price

275

Analyst Recom

Performance Q

38.49

Relative Volume

1.17

Beta

0.49

Ticker: KRYS

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-11	KRYS	246.94	2.26	0.27	8102
2025-12-12	KRYS	244.66	2.25	0.08	8127
2025-12-15	KRYS	243.08	2.24	0.00	8162
2025-12-16	KRYS	238.77	1.58	0.06	9200
2025-12-17	KRYS	235.94	1.59	0.48	9189
2025-12-18	KRYS	233.7	1.57	0.08	9550
2025-12-19	KRYS	239.8	1.48	0.01	9786
2025-12-22	KRYS	249.42	0.57	0.15	2196
2025-12-23	KRYS	253.62	0.54	0.03	2277
2025-12-26	KRYS	252.42	0.33	2.26	3364
2025-12-29	KRYS	253.92	0.32	0.06	3364
2025-12-30	KRYS	248.16	0.30	2.50	3514
2025-12-31	KRYS	246.52	0.31	1.00	3529
2026-01-02	KRYS	246.64	0.35	1.69	3636
2026-01-05	KRYS	244.66	0.35	16.61	3629
2026-01-06	KRYS	249.26	0.53	0.00	4132
2026-01-07	KRYS	246.15	0.44	0.03	4692
2026-01-08	KRYS	248.45	0.44	1.44	4674
2026-01-09	KRYS	261.4	0.56	0.17	5131
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-11	KRYS	246.56	5.0	221.8	6.00
2025-12-12	KRYS	244.84	5.0	207.2	6.00
2025-12-15	KRYS	242.98	5.0	207.7	6.00
2025-12-16	KRYS	242.98	5.0	203.5	6.00
2025-12-17	KRYS	235.68	5.0	205.3	6.00
2025-12-18	KRYS	233.71	5.0	206.8	6.00
2025-12-19	KRYS	241.10	5.0	223.9	6.00
2025-12-22	KRYS	248.90	5.0	224.2	6.54
2025-12-23	KRYS	253.63	5.0	215.9	6.54
2025-12-26	KRYS	252.35	5.0	212.2	6.54
2025-12-29	KRYS	253.74	5.0	213.0	6.54
2025-12-30	KRYS	248.04	5.0	201.4	6.54
2025-12-31	KRYS	246.54	5.0	208.2	6.54
2026-01-02	KRYS	246.65	5.0	210.7	6.54
2026-01-05	KRYS	244.74	5.0	206.8	6.54
2026-01-06	KRYS	249.26	5.0	218.1	6.54
2026-01-07	KRYS	246.26	5.0	205.3	6.54
2026-01-08	KRYS	248.74	5.0	214.4	6.54
2026-01-09	KRYS	261.58	5.0	231.3	6.54
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-11	KRYS	-4.62	1.96	11.53
2025-12-12	KRYS	-4.62	1.96	11.53
2025-12-15	KRYS	-4.62	1.93	11.50
2025-12-16	KRYS	-4.69	1.93	11.50
2025-12-17	KRYS	-4.69	1.93	11.50
2025-12-18	KRYS	-4.69	1.93	11.50
2025-12-19	KRYS	-4.69	1.93	11.50
2025-12-22	KRYS	-4.69	1.93	11.50
2025-12-23	KRYS	-4.69	1.93	11.50
2025-12-26	KRYS	-4.69	1.93	10.91
2025-12-29	KRYS	-4.69	1.93	10.91
2025-12-30	KRYS	-4.69	1.93	10.91
2025-12-31	KRYS	-4.69	1.93	10.91
2026-01-02	KRYS	-4.69	1.93	10.91
2026-01-05	KRYS	-4.69	1.93	10.91
2026-01-06	KRYS	-4.69	1.93	10.91
2026-01-07	KRYS	-4.69	1.93	10.91
2026-01-08	KRYS	-4.69	1.93	10.91
2026-01-09	KRYS	-4.69	1.93	10.91
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

2.66

Avg. EPS Est. Current Quarter

1.61

Avg. EPS Est. Next Quarter

1.52

Insider Transactions

-4.69

Institutional Transactions

1.93

Beta

0.49

Average Sales Estimate Current Quarter

105

Average Sales Estimate Next Quarter

120

Fair Value

224.15

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

1.6

Max Drawdown 5-Year %

-53.4

Target Price

275

P/E

39.21

Forward P/E

33.86

PEG

0.67

P/S

20.31

P/B

6.66

P/Free Cash Flow

45.78

EPS

6.67

Average EPS Est. Cur. Y

6.54

EPS Next Y. (Est.)

8.44

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

53.3

Relative Volume

1.17

Return on Equity vs Sector %

-9.7

Return on Equity vs Industry %

5.6

EPS 1 7Days Diff

0.5

EPS 1 30Days Diff

0.53

EBIT Estimation

231.3

Krystal Biotech, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 275

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today

news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance

stock history KRYS – Krystal Biotech, Inc. invest stock market

stock prices KRYS premarket after hours

ticker KRYS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: KRYS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y